Literature DB >> 11160013

The Common vaccine adjuvant aluminum hydroxide up-regulates accessory properties of human monocytes via an interleukin-4-dependent mechanism.

M Ulanova1, A Tarkowski, M Hahn-Zoric, L A Hanson .   

Abstract

Aluminum adjuvants are widely used in human vaccines based on their ability to enhance antibody production. However, the mechanisms underlying these effects remain unknown. In the present study we assessed the direct in vitro effect of aluminum hydroxide on human peripheral blood monocytes, specifically with regard to its impact on the phenotype and functional properties of this cell population. Our results revealed significant changes in the accessory properties of monocytes following short-term exposure of cultured cells to aluminum hydroxide. Thus, flow cytometry analyses showed an increase in the expression of major histocompatibility complex (MHC) class II, CD40, CD54, CD58, CD83, and CD86 molecules on the monocytes. In addition, many cells in the cultures containing aluminum hydroxide acquired typical dendritic morphology. Increased synthesis of interleukin-4 (IL-4) mRNA, but not gamma interferon mRNA, was also noted after exposure to aluminum hydroxide. The increase in cell surface expression of MHC class II did not occur in the presence of neutralizing IL-4 antibody or in cultures of highly purified monocytes or CD4-depleted mononuclear cells. Our findings suggest that aluminum hydroxide directly stimulates monocytes to produce proinflammatory cytokines activating T cells. Activated Th2 cells release IL-4, which in turn can induce an increase in the expression of MHC class II molecules on monocytes. The increase in the expression of antigen-presenting and costimulatory molecules leads to enhanced accessory functions of monocytes. These properties of aluminum hydroxide observed in vitro may explain its potent in vivo adjuvant effect.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11160013      PMCID: PMC97997          DOI: 10.1128/IAI.69.2.1151-1159.2001

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  43 in total

1.  Modulation of the human immune response by the non-toxic and non-pyrogenic adjuvant aluminium hydroxide: effect on antigen uptake and antigen presentation.

Authors:  J W Mannhalter; H O Neychev; G J Zlabinger; R Ahmad; M M Eibl
Journal:  Clin Exp Immunol       Date:  1985-07       Impact factor: 4.330

2.  Selective regulation of chemotactic lymphokine production. I. Selective potentiation of eosinophil chemotactic lymphokine production in alum hydroxy gel- and Bordetella pertussis vaccine-treated guinea pigs.

Authors:  K Sakata; K Tashiro; M Hirashima; H Hayashi
Journal:  J Immunol       Date:  1985-11       Impact factor: 5.422

3.  Aluminium hydroxide adjuvant initiates strong antigen-specific Th2 responses in the absence of IL-4- or IL-13-mediated signaling.

Authors:  J M Brewer; M Conacher; C A Hunter; M Mohrs; F Brombacher; J Alexander
Journal:  J Immunol       Date:  1999-12-15       Impact factor: 5.422

4.  Human blood dendritic cells selectively express CD83, a member of the immunoglobulin superfamily.

Authors:  L J Zhou; T F Tedder
Journal:  J Immunol       Date:  1995-04-15       Impact factor: 5.422

5.  Establishment and characterization of a human acute monocytic leukemia cell line (THP-1).

Authors:  S Tsuchiya; M Yamabe; Y Yamaguchi; Y Kobayashi; T Konno; K Tada
Journal:  Int J Cancer       Date:  1980-08       Impact factor: 7.396

6.  Establishment of a human cell line (Mono Mac 6) with characteristics of mature monocytes.

Authors:  H W Ziegler-Heitbrock; E Thiel; A Fütterer; V Herzog; A Wirtz; G Riethmüller
Journal:  Int J Cancer       Date:  1988-03-15       Impact factor: 7.396

7.  IL-4R alpha and gamma chain expression in LPS- and IL-4-stimulated MONO-MAC-6 cells.

Authors:  H Quentmeier; K Kolsdorf; M Zaborski; H G Drexler
Journal:  Leukemia       Date:  1995-02       Impact factor: 11.528

8.  Induction of Ia and H-2 antigens on a macrophage cell line by immune interferon.

Authors:  D P King; P P Jones
Journal:  J Immunol       Date:  1983-07       Impact factor: 5.422

9.  B70/B7-2 is identical to CD86 and is the major functional ligand for CD28 expressed on human dendritic cells.

Authors:  C Caux; B Vanbervliet; C Massacrier; M Azuma; K Okumura; L L Lanier; J Banchereau
Journal:  J Exp Med       Date:  1994-11-01       Impact factor: 14.307

10.  Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products.

Authors:  F Sallusto; M Cella; C Danieli; A Lanzavecchia
Journal:  J Exp Med       Date:  1995-08-01       Impact factor: 14.307

View more
  42 in total

Review 1.  The development and use of vaccine adjuvants.

Authors:  Robert Edelman
Journal:  Mol Biotechnol       Date:  2002-06       Impact factor: 2.695

Review 2.  Recent advances in vaccine adjuvants.

Authors:  Manmohan Singh; Derek T O'Hagan
Journal:  Pharm Res       Date:  2002-06       Impact factor: 4.200

3.  Effect of adjuvants and route of immunizations on the immune response to recombinant plague antigens.

Authors:  Sabena Uddowla; Lucy C Freytag; John D Clements
Journal:  Vaccine       Date:  2007-10-02       Impact factor: 3.641

4.  Adjuvant formulations possess differing efficacy in the potentiation of antibody and cell mediated responses to a human malaria vaccine under selective immune genes knockout environment.

Authors:  George S Hui; Caryn N Hashimoto
Journal:  Int Immunopharmacol       Date:  2008-04-03       Impact factor: 4.932

5.  Toward understanding the mechanism underlying the strong adjuvant activity of aluminum salt nanoparticles.

Authors:  Tinashe B Ruwona; Haiyue Xu; Xu Li; Amber N Taylor; Yan-Chun Shi; Zhengrong Cui
Journal:  Vaccine       Date:  2016-05-05       Impact factor: 3.641

6.  Chitosan and chitosan nanoparticles as adjuvant in local Rift Valley Fever inactivated vaccine.

Authors:  Ashgan F El-Sissi; Farida H Mohamed; Nadia M Danial; Ali Q Gaballah; Korany A Ali
Journal:  3 Biotech       Date:  2020-02-04       Impact factor: 2.406

7.  Adjuvant effects of aluminium hydroxide-adsorbed allergens and allergoids - differences in vivo and in vitro.

Authors:  B Heydenreich; I Bellinghausen; L Lund; H Henmar; G Lund; P Adler Würtzen; J Saloga
Journal:  Clin Exp Immunol       Date:  2014-06       Impact factor: 4.330

8.  Recombinant GRA4 or ROP2 protein combined with alum or the gra4 gene provides partial protection in chronic murine models of toxoplasmosis.

Authors:  Valentina Martin; Alicia Supanitsky; Pablo C Echeverria; Silvana Litwin; Tamara Tanos; Adolfo R De Roodt; Eduardo A Guarnera; Sergio O Angel
Journal:  Clin Diagn Lab Immunol       Date:  2004-07

9.  Enhancement of in vivo and in vitro immune functions by a conformationally biased, response-selective agonist of human C5a: implications for a novel adjuvant in vaccine design.

Authors:  Edward L Morgan; Brandon N Morgan; Elisabeth A Stein; Elizabeth L Vitrs; Marilyn L Thoman; Sam D Sanderson; Joy A Phillips
Journal:  Vaccine       Date:  2009-10-15       Impact factor: 3.641

10.  Safety and immunogenicity of a recombinant Plasmodium falciparum AMA1 malaria vaccine adjuvanted with Alhydrogel, Montanide ISA 720 or AS02.

Authors:  Meta Roestenberg; Ed Remarque; Erik de Jonge; Rob Hermsen; Hildur Blythman; Odile Leroy; Egeruan Imoukhuede; Soren Jepsen; Opokua Ofori-Anyinam; Bart Faber; Clemens H M Kocken; Miranda Arnold; Vanessa Walraven; Karina Teelen; Will Roeffen; Quirijn de Mast; W Ripley Ballou; Joe Cohen; Marie Claude Dubois; Stéphane Ascarateil; Andre van der Ven; Alan Thomas; Robert Sauerwein
Journal:  PLoS One       Date:  2008-12-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.